XCXin-Gang Cui

Xin-Gang Cui

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xin-Gang Cui has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Hai Huang

    Department of Urinary Surgery of Changzheng Hospital, Second Military Medical University, Huangpu, Shanghai 200003, P.R. China

    9 shared publications
  • Lu Chen

    Department of Urinary Surgery of Changzheng Hospital, Second Military Medical University, Huangpu, Shanghai 200003, P.R. China

    9 shared publications
  • Lin Li

    Department of Urinary Surgery of Changzheng Hospital, Second Military Medical University, Huangpu, Shanghai 200003, P.R. China

    7 shared publications
  • Xiu-Wu Pan

    Department of Urinary Surgery of Changzheng Hospital, Second Military Medical University, Huangpu, Shanghai 200003, P.R. China

    7 shared publications
  • Xi Liu

    Department of Urinary Surgery, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China

    6 shared publications
  • Yi Huang

    Department of Urinary Surgery of Changzheng Hospital, Second Military Medical University, Huangpu, Shanghai 200003, P.R. China

    5 shared publications

Latest Publications

  • Open Access

    [Corrigendum] Icaritin acts synergistically with epirubicin to suppress bladder cancer growth through inhibition of autophagy

    by Xiu-Wu Pan, Lin Li, Yi Huang, Hai Huang, Dan-Feng Xu, Yi Gao, Lu Chen, Ji-Zhong Ren, Jian-Wei Cao, Yi Hong, et al.

    Following the publication of the above article, the authors have contacted the Editorial Office to explain that they had noticed that, in Fig. 4 on p. 339, the same western blot data for the ATG5 protein had inadvertently been included for the T24 and the BT5637 cell lines for the 72 h experiments (the lower panels of blots). However, the authors had retained their original data, and were able to identify how this error occurred. The revised version of Fig. 4, now showing the correct data for the ATG5 protein for the 72 h experiment with the BT5637 cell line, is shown on the next page. Note that this error did not affect the overall results and conclusions reported in the paper. The authors are grateful to the Editor of Oncology Reports for granting them the opportunity to publish this corrigendum, and all the authors agree with its publication; furthermore, they apologize to the readership of the journal for any inconvenience caused. [Oncology Reports 35: 334‑342, 2016; DOI: 10.3892/or.2015.4335]

  • Open Access

    [Corrigendum] SMC1A promotes growth and migration of prostate cancer in vitro and in vivo

    by Xiu-Wu Pan, Si-Shun Gan, Jian-Qing Ye, Ying-Hui Fan, Yi Hong, Chuan-Min Chu, Yi Gao, Lin Li, Xi Liu, Lu Chen, et al.

    Subsequently to the publication of the above article, an interested reader drew to the authors’ attention that, on p. 1969, two pairs of panels shown for the DU145 data appeared to contain overlaps, such that they may have been derived from the same original source (specifically, relating to the shCon and the shSMC1A experiments). The authors have referred back to their original data, and realize that inadvertent errors were made during the assembly of these figures. The corrected version of Fig. 5, showing discrete representative images for the shCon and the shSMC1A experiments with the DU145 cell line, is shown on the next page. All the authors agree to this corrigendum. Note that the revisions made to this figure do not adversely affect the results reported in the paper, or the conclusions stated therein. The authors regret that Fig. 5 was not presented in its correct form in their paper, thank the Editor of International Journal of Oncology for granting them the opportunity to publish this corrigendum, and offer their apologies to the Editor and to the readers of the Journal. [the original article was published in International Journal of Oncology 49: 1963-1972, 2016; DOI: 10.3892/ijo.2016.3697]

  • Open Access

    PPP5C promotes cell proliferation and survival in human prostate cancer by regulating of the JNK and ERK1/2 phosphorylation

    by Jian-Min Lv, Lu Chen, Yi Gao, Hai Huang, Xiu-Wu Pan, Xi Liu, Ming Chen, Fa-Jun Qu, Lin Li, Jun-Kai Wang, et al.

    Background: Prostate cancer (PCa) is one of the most common malignancies and a major leading cause of cancer-related deaths in males. And it is necessary to explore new molecular targets to enhance diagnosis and treatment level of the PCa. Serine/threonine protein phosphatase 5 (PPP5C) is a vital molecule that Involve in complex cell physiological activity. Purpose: The objective of this study was to detecte the expression level of PPP5C in the tissue of prostate cancer patients and further discussed the PPP5C biological function and mechanisms on the PCa. Methods: The expression level of PPP5C was analyzed by immunohistochemistry and ONCOMINE datasets. Lentivirus-mediated short hairpin RNA (shRNA) was constructed to silence the expression of PPP5C in prostate cancer cell. Cell viability and proliferation were measured using MTT and colony formation, and the cell cycle and apoptosis was analyszed by flow cytometry. The changes of downstream protein level and protein phosphorylation level were detected by western blot. Results: PPP5C was highly expressed in PCa tissue as analyzed by immunohistochemistry and ONCOMINE datasets. PPP5C Knockdown inhibited cell proliferation and colony formation in PCa cells. Flow cytometry analysis showed that DU145, PC3 and 22RV1 PCa cells deprived of PPP5C were arrested in G0/G1 phase and became apoptotic. Western blot analysis indicated that PPP5C knockdown could promote JNK and ERK phosphorylation. Conclusion: Our study indicated that the PPP5C may become a new potential diagnostic biomarker and therapeutic target for the PCa.


  • Open Access

    High expression of PDLIM5 facilitates cell tumorigenesis and migration by maintaining AMPK activation in prostate cancer

    by Xi Liu, Lu Chen, Hai Huang, Jian-Min Lv, Ming Chen, Fa-Jun Qu, Xiu-Wu Pan, Lin Li, Lei Yin, Xin-Gang Cui, et al.

    High expression of PDLIM5 facilitates cell tumorigenesis and migration by maintaining AMPK activation in prostate cancer High expression of PDLIM5 facilitates cell tumorigenesis and migration by maintaining AMPK activation in prostate cancer


  • Identification of prognostic markers of high grade prostate cancer through an integrated bioinformatics approach

    by Hai Huang, Qin Zhang, Chen Ye, Jian-Min Lv, Xi Liu, Lu Chen, Hao Wu, Lei Yin, Xin-Gang Cui, Dan-Feng Xu, et al.

    Purpose Prostate cancer is one of the leading causes of cancer death for male. In the present study, we applied an integrated bioinformatics approach to provide a novel perspective and identified some hub genes of prostate cancer. Method Microarray data of fifty-nine prostate cancer were downloaded from Gene Expression Omnibus. Gene Ontology and pathway analysis were applied for differentially expressed genes between high and low grade prostate cancer. Weighted gene coexpression network analysis was applied to construct gene network and classify genes into different modules. The most related module to high grade prostate cancer was identified and hub genes in the module were revealed. Ingenuity pathway analysis was applied to check the chosen module’s relationship to high grade prostate cancer. Hub gene’s expression profile was verified with clinical samples and a dataset from The Cancer Genome Atlas project. Result 3193 differentially expressed genes were filtered and gene ontology and pathway analysis revealed some cancer- and sex hormone-related results. Weighted gene coexpression network was constructed and genes were classified into six modules. The red module was selected and ingenuity pathway analysis confirmed its relationship with high grade prostate cancer. Hub genes were identified and their expression profile was also confirmed. Conclusion The present study applied integrate bioinformatics approaches to generate a holistic view of high grade prostate cancer and identified hub genes could serve as prognosis markers and potential treatment targets.


  • Open Access

    Epithelial-mesenchymal transition induced by GRO-α-CXCR2 promotes bladder cancer recurrence after intravesical chemotherapy

    by Lu Chen, Xiu-Wu Pan, Hai Huang, Yi Gao, Qi-Wei Yang, Lin-Hui Wang, Xin-Gang Cui, Dan-Feng Xu

    Epithelial-mesenchymal transition induced by GRO-α-CXCR2 promotes bladder cancer recurrence after intravesical chemotherapy Epithelial-mesenchymal transition induced by GRO-α-CXCR2 promotes bladder cancer recurrence after intravesical chemotherapy


  • Open Access

    EIF3D silencing suppresses renal cell carcinoma tumorigenesis via inducing G2/M arrest through downregulation of Cyclin B1/CDK1 signaling

    by Xiu-Wu Pan, Lu Chen, Yi Hong, Dan-Feng Xu, Xi Liu, Lin Li, Yi Huang, Li-Ming Cui, Si-Shun Gan, Qi-Wei Yang, et al.

    There are no effective therapies for advanced renal cell carcinoma (RCC), except for VEGFR inhibitors with only ~50% response rate. To identify novel targets and biomarkers for RCC is of great importance in treating RCC. In this study, we observed that eukaryotic initiation factor 3d (EIF3D) expression was significantly increased in RCC compared with paracarcinoma tissue using immunohistochemistry staining and western blot analysis. Furthermore, bioinformatics meta-analysis using ONCOMINE microarray datasets showed that EIF3D mRNA expressions in CCRCC tissue specimens were significantly higher than that in normal tissue specimens. In addition, RCC tissue microarray demonstrated that elevated EIF3D expression was positively correlated with TNM stage and tumor size. EIF3D silencing in human 786-O and ACHN CCRCC cell lines by RNA interference demonstrated that EIF3D knockdown obviously inhibited cell proliferation and colony formation, caused G2/M arrest through downregulation of Cyclin B1 and Cdk1 and upregulation of p21, and induced apoptosis shown by sub-G1 accumulation and RARP cleavage. Moreover, correlation analysis using ONCOMINE microarray datasets indicated that increased EIF3D mRNA expression was positively correlated to PCNA, Cyclin B1 and CDK1 mRNA expression in RCC. Collectively, these results provide reasonable evidences that EIF3D may function as a potential proto-oncogene that participates in the occurrence and progression of RCC.


  • Open Access

    Overexpression of USP39 predicts poor prognosis and promotes tumorigenesis of prostate cancer via promoting EGFR mRNA maturation and transcription elongation

    by Yi Huang, Xiu-Wu Pan, Lin Li, Lu Chen, Xi Liu, Jian-Lei Lu, Xiao-Mei Zhu, Hai Huang, Qi-Wei Yang, Jian-Qing Ye, et al.

    Overexpression of USP39 predicts poor prognosis and promotes tumorigenesis of prostate cancer via promoting EGFR mRNA maturation and transcription elongation


  • Open Access

    Quality-of-life outcomes and unmet needs between ileal conduit and orthotopic ileal neobladder after radical cystectomy in a Chinese population: a 2-to-1 matched-pair analysis

    by Yi Huang, Xiuwu Pan, Qiwei Zhou, Hai Huang, Lin Li, Xingang Cui, Guodong Wang, Ren Jizhong, Lei Yin, Danfeng Xu, et al.

    Health-related quality-of-life (HRQoL) is an important consideration after radical cystectomy (RC). Lack of effective ways to assess HRQoL after RC and unawareness of disease-specific problems related to ileal conduit (IC) and orthotopic ileal neobladder (OIN) are serious problems. The present study was to evaluate and compare morbidity and HRQoL between IC and OIN after RC, and examine their unmet needs in the two groups. A retrospective analysis was made of 294 patients treated with RC in our hospital between 2007 and 2013. Matched pair analysis was used to determine the patients of IC and OIN groups. Patient HRQoL between IC and OIN groups was assessed using the bladder-specific bladder cancer index (BCI) and European Organization for Research and Treatment of Cancer Body Image scale (BIS) questionnaires. Unmet information of patients undergoing these two urinary diversions was recorded through individual interviews. Of the 117 included patients, 39 patients were treated with OIN and the other 78 matched patients with IC as controls for matched pair analysis. There was no significant difference in baseline characteristics between the two groups. OIN patients showed significantly better BIS scores in terms of HRQoL outcomes after RC at a short-term (1 year) follow-up level between the two groups. Interestingly, urinary bother (UB) and urinary function (UF) were poor in OIN patients at the one-year follow-up level, but there was no significant difference in UB between the two groups at the long term follow-up level. Unmet needs analysis showed that OIN patients had a more positive attitude towards treatment and participated in physical and social activities more positively, although they may have more urine leakage problems. The mean BIS score in OIN group patients was significantly better than that in IC group patients at the one-year follow-up level, but there was no significant difference at the long-term follow-up level. Due attention should be paid to some particular unmet needs in individual patients in managing the two UD modalities.


  • Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma

    by Xiuwu Pan, Hai Huang, Yi Huang, Bing Liu, Xingang Cui, Sishun Gan, Jianqing Ye, Danfeng Xu, Lu Chen, Qiwei Zhou, et al.